PATENT CLAIM ANALYSIS

Application Number: 16368992
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "364000"]

Abstract:
The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.

Claim (Index 29):
The method of  claim 21 , wherein the first dose is administered in the morning, the second dose is administered at midday and the third dose is administered in the evening of the 24 hour period.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 99.0
- Lexical Diversity: 1.45652
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14221352', '16021419', '15643724', '15875296', '15345748']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.834456625976876
- 35 USC 102 Novelty (BERT): 0.5888187545641385
- Combined Prediction Score: 0.8098928388356023
- Mean Citation Score: 531.704782
- Max Citation Score: 537.7344
- Similarity Product: 396.19787419967656

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test